Why the United States Precision Medicine Market Is Growing With the Shift Toward Individualized Care

A move away from the one-size-fits-all approach in medicine - and toward a more individualistic approach that leverages genetic information‚ biomarkers‚ advanced analytics and digital‌ technologies to better understand and serve the needs of each unique patient - has been positively impacting the precision medicine market in the United States‚ where the goal is to more closely align therapies with the biology of disease․ The US precision medicine market‚ according to IMARC Group‚ was valued at USD 38․4 billion in 2024 and is expected to reach USD 43․2 billion by 2033‚ expanding at‌ a CAGR of 11․7% from 2025 to 2033․

The primary market driver is the growth‌ in chronic disease prevalence․ According to a report by IMARC‚ the increasing prevalence of cancer and cardiovascular disease‚ the growing volume of healthcare data‚ an increase in genome research‚ an increase in the use of artificial intelligence and machine‌ learning‚ government support for precision medicine and collaborations between health systems and technology companies are all driving the growth of the precision medicine market․

Another key trend in the market is a growing focus on pharmacogenomics‚ the study‌ of how genes affect a person's response to drugs․ According to IMARC‚ the United States market is being driven‌ by the increased application of pharmacogenomics in the development of drugs and clinical practices․ One example it uses is when BioStrand and PGxAI announced a collaboration in‌ June 2024 to develop an AI model to help prescribe treatment according to pharmacogenomics results․ It matters because it shows precision‌ medicine is becoming more actionable in real treatment decisions‚ not just research settings․

Another area of growth‚ according to IMARC‚ is next-generation sequencing (NGS)‚ which is faster and cheaper than older sequencing technologies‚ and is‌ said to be driving market growth․ The report notes Illumina's October 2024 release of the MiSeq i100 Series as an example‌ of how the sequencing landscape is being brought to more laboratories․ It describes how increased access to NGS allows for biomarker discovery‚ more rare mutations‌ being identified‚ and more personalized patient care‚ particularly in oncology․

Artificial intelligence is also being used in increasing amounts․ According to IMARC‚ the convergence of AI and digital health technologies is one of the main market drivers‚ as it analyzes healthcare data on a large scale‚ predicts the risk of diseases and customizes interventions․ The report further references HIMSS Market Insights‚ which to October 2024 found that more than 60% of healthcare organizations say they plan to implement AI applications such as generative AI‚ predictive analytics and workflow automation over the next three years‚ and that precision medicine is becoming increasingly integrated within the overall digitization of healthcare․

What makes it interesting is that this market is being extended outwards on many levels‚ not only improved diagnostics․ It is also being extended so as to provide important links between diagnostics‚ drug development‚ clinical decision making‚ patient management and long-term preventative medicine․ The IMARC report also highlighted that the growth of direct to consumer genetic testing is helping to create greater awareness and demand from patients‚ as well as the development of partnerships between research institutions and clinical organizations to help moves discoveries more quickly into products to support patients better․

For instance‚ IMARC segments the market by product into consumables‚ instruments‚ and services; by technology into big data analytics‚ bioinformatics‚ gene sequencing‚ drug discovery‚ and companion diagnostics‚ among others; and by application and end user (biotechnology and pharmaceutical companies‚ hospitals‚ CROs‚ and research laboratories)․ By application‚ the market is segmented into oncology‚ central nervous system (CNS)‚ immunology‚ respiratory‚ infectious diseases and others․ By end user‚ the market is segmented into hospitals and clinics‚ diagnostic centers‚ pharma and biotech companies‚ healthcare IT companies and others․ That range of work shows how wide the opportunity is: precision medicine is not a small niche but a growing ecosystem of research‚ diagnostics‚ treatment‚ and digital health․

Oncology is one of the largest applications․ According to IMARC‚ cancer-related precision medicine has gained meaningful traction in the United States‚ as genomic profiling and targeted therapies allow for treatment to be personalized based on a patient's tumor profile․ That matters‚ because oncology is probably the area where precision medicine is most likely to have effect: more closely matched treatment to disease biology should equal better outcomes and fewer side effects․

The United States precision medicine market is a reflection of an active transition in medicine from a one-size-fits-all approach to customizing healthcare based on the unique qualities of each patient․ With the continued advancement of genomics‚ bioinformatics‚ artificial intelligence and sequencing technologies‚ precision medicine has the potential to become an important part of healthcare as a service․

For readers who want a closer look at forecast data, technology trends, and application segments, the full IMARC Group study offers more detailed insight.